Bioavailability enhancers

Details Bioavailability enhancers Bioavailability enhancers

1989-09-26

1992-06-30

Friedman, S. J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514356, A61K 3144, A61K 3152

Patent

active

051263483

ABSTRACT:
Vasodilators and theophylline.

REFERENCES:
EPO Publication 106,335, published Apr. 25, 1984.
Ther, L. and Winne, D., (1971), "Drug Absorption", pp. 57-69.
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 53.
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 108.
McLean, A. J., (1978), Clin. Pharmacol. Ther., 24:5-10.
Schneck, D. W. and Vary, J. E., (1984), Clin. Pharmacol. Ther., 35:447-453.
Condorelli, L., (1964), in Niacin in Vascular Disorders and Hyperlipemia, R. Altschul (ed.), pp. 162-164. (See Ref. O).
Svedmyr, N. et al., (1970), in Metabolic Effects of Nicotinic Acid and its Derivatives, K. F. Gey and L. A. Carlson (eds.), Hans Huber Pub., pp. 1085-1098.
Grigoleit, H.-G. et al., (1976), Therapiewoche, 26:5722-5729.
Lindberg, N.-O., (1970), Acta Pharm. Svecica, 7:23-28.
Waller, A. R., (1985), Arnzeim.-Forsch./Drug Res., 35:489-492.
Mosher, L. R., (1970), Am. J. Psychiat., 126:1290-1296.
Abramson, D. I. et al., (1940), Am. J. Med. Sci., 200:96-102.
Popkin, R. J., (1939), Am. Heart J., 18:697-704.
Condorelli, L., (1964), in Niacin in Vascular Disorders and Hyperlipemia, R. Altschul (ed.), pp. 156-207.
Andersson, R. G. G. et al., (1977), Acta Pharmacol. et Toxicol., 41:1-10.
Svedmyr, N. et al., (1969), Clin. Pharmacol. Therapeut., 10:559-570.
Bechgaard, H. and Jespersen, S., (1977), J. Pharmaceut. Sci., 66:871-872.
Nickerson, M., (1975), The Pharmacological Basis of Therapeutics, Chapter 34, L. S. Goodman and A. Filman (eds.), pp. 745-760.
Stella, V. J. et al., (Feb. 1978), Kans. Pharmacy, pp. 12-13.
Levy, G., (1963), in Salicylates, an International Symp., Dixon et al. (eds.), pp. 9-17.
Koysooko et al., (1974), Clin. Pharmacol. Therapeut., 15:454-460.
Levy, G. et al., (1974), Pediatrics, 53:873-876.
Hendeles, L. et al., (1985), Chest, 88:103S-111S.
Piafsky, K. M. and Ogilvie, R. I., (1975), New Engl. J. Med., 292:1218-1222.
Brattsand, R. and Harthon, L., (1975), Acta Pharmacol. Toxicol., 36:203-214.
Cadwallader, D. E., (1971), Biopharmaceutics and Drug Interactions, (Roche Laboratories, Nutley, N.J.), p. 48.

Affiliated with

Also associated with

Rating

Bioavailability enhancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bioavailability enhancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioavailability enhancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1863956